Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duration of Perioperative Antibiotic Prophylaxis in Pancreatoduodenectomy
NCT07043855Phase 3Enrolling by invitation
- Sponsor
- Asan Medical Center
- Start
- May 2026
- Primary completion
- Oct 2028
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised trial of cefazolin in surgical site infection (SSI) (2 arms), sponsored by Asan Medical Center. Primary endpoint: Surgical site infection at 30 days. Started May 2026; status: enrolling by invitation.
02
Drugs
cefazolin
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT07043855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07043855.